1. Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: T-Lymphocyte Interferon-γ Receptor Binding in Patients With Myasthenia Gravis Arch Neurol. 1999;56(8):933-938. doi:10.1001/archneur.56.8.933 Single-color fluorescent-activated cell sorter analysis. Cell suspensions (from either freshly isolated mononuclear cells [a] or purified lymphocyte cell cultures [b]), 100 µL, were incubated in the dark for 20 minutes with 5 µL of fluorescein-isothiocyanate–conjugated monoclonal antibodies against human CD3, CD4, or CD8 (specific markers for total T, T-helper, and T-cytotoxic cells). Samples were counted through a flow cytometer (Epics XL MCL; Coulter Electronics, Luton, England) equipped with a single 15-mW argon ion laser (excitation wavelength of 488 nm in combination with a 530-nm "band-pass" filter). Fluorescein-isothiocyanate–conjugated mouse IgG was used to evaluate nonspecific fluorescence. Overlayed histograms of CD3 + cells in freshly isolated and purified cell cultures from a patient with myasthenia gravis (A) and a control (B) are reported. Overlayed histograms of freshly isolated and purified CD4 + cells (C) and CD8 + cells (D) from a patient with myasthenia gravis are also reported. Figure Legend:

2. Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: T-Lymphocyte Interferon-γ Receptor Binding in Patients With Myasthenia Gravis Arch Neurol. 1999;56(8):933-938. doi:10.1001/archneur.56.8.933 Highly enriched T lymphocytes have been incubated with 0.5 ng of iodine 125 ( 125 I)–labeled interferon γ (IFN-γ) and the above indicated amounts of unlabeled IFN-γ. A, The binding of 125 I–IFN-γ is expressed as a percentage of the binding in the absence of unlabeled IFN-γ. B, The competitive binding data have been analyzed by the method of Scatchard. Figure Legend:

3. Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: T-Lymphocyte Interferon-γ Receptor Binding in Patients With Myasthenia Gravis Arch Neurol. 1999;56(8):933-938. doi:10.1001/archneur.56.8.933 Interferon-γ maximal receptor number values were determined in T lymphocytes from patients with myasthenia gravis and healthy controls (see "T-Lymphocyte IFN-γ Binding" subsection of the "Materials and Methods" section for details). The difference between patients and controls was significant. Each point in the plot represents the maximal receptor value for each subject (P<.001). Figure Legend:

4. Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: T-Lymphocyte Interferon-γ Receptor Binding in Patients With Myasthenia Gravis Arch Neurol. 1999;56(8):933-938. doi:10.1001/archneur.56.8.933 Interferon-γ binding on T-helper lymphocytes was assayed in patients with myasthenia gravis (MG) who had distinct disease forms, differently treated (see the "Separation of T Lymphocytes From Peripheral Blood" subsection of the "Materials and Methods" section for details). The difference between patients and controls was significant. Each column represents the mean maximal receptor value for each subjects' subgroup. Bars represent SD (P<.001). Figure Legend:

5. Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: T-Lymphocyte Interferon-γ Receptor Binding in Patients With Myasthenia Gravis Arch Neurol. 1999;56(8):933-938. doi:10.1001/archneur.56.8.933 Interleukin 2 levels in serum samples from patients with myasthenia gravis and healthy controls. Interleukin 2 was assayed by using a commercially available kit. The difference between patients and controls was significant. Dashed line indicates mean values for patients and controls (P<.001). Figure Legend:

6. Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: T-Lymphocyte Interferon-γ Receptor Binding in Patients With Myasthenia Gravis Arch Neurol. 1999;56(8):933-938. doi:10.1001/archneur.56.8.933 Soluble interleukin 2 receptor levels in serum samples from patients with myasthenia gravis and healthy controls. Interleukin 2 receptors were determined by means of an immunoenzymatic assay. The difference between patients and controls was significant. Solid lines indicate mean values for patients and controls (P<.001). Figure Legend:

7. Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: T-Lymphocyte Interferon-γ Receptor Binding in Patients With Myasthenia Gravis Arch Neurol. 1999;56(8):933-938. doi:10.1001/archneur.56.8.933 Linear regression analysis on T-lymphocyte interferon-γ binding and serum interleukin 2 (IL-2) levels in patients with myasthenia gravis. The open circles indicate serum IL-2. Figure Legend:

8. Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: T-Lymphocyte Interferon-γ Receptor Binding in Patients With Myasthenia Gravis Arch Neurol. 1999;56(8):933-938. doi:10.1001/archneur.56.8.933 Linear regression analysis on T-lymphocyte interferon-γ binding and serum soluble interleukin 2 (IL-2) receptor levels in patients with myasthenia gravis. The open circles indicate soluble IL-2 receptors. Figure Legend: